Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis

NCT ID: NCT06216028

Last Updated: 2024-05-24

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 374 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-30
• Study Completion Date: 2026-12-31

Brief Summary

The purpose of the ACCELERATE3 trial is to assess the efficacy of a single intra-articular (IA) injection of autologous BMAC, in one or both knees, compared to a single IA injection of Standard of Care (SOC) in patients with mild to severe knee OA.

Detailed Description

A Pan-Canadian, Phase 3, open-label, randomized trial of bone marrow aspirate concentrate (BMAC) administration in patients with mild to severe knee OA. A total of 374 eligible patients will be randomized to BMAC or Standard of Care (SOC). Patients randomized to the interventional arm (BMAC) will have a sample of bone marrow taken (from their pelvic region) and processed at the bedside for immediate delivery back to the patient via intra-articular (IA) injection into one or both knees.

All randomized patients will be followed for 48 weeks. Blood will be collected at scheduled visits for analysis. Adverse events will be monitored throughout the trial. Assessments will be performed by physical exam and standardized questionnaires related to the physical function, health, and pain of each participant will be conducted.

Conditions

Knee Osteoarthritis; Musculoskeletal Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Standard of Care

Standard of care IA injection may include cortisone or hyaluronic acid (HA) as per discretion of the Principal Investigator

Group Type: NO_INTERVENTION

No interventions assigned to this group

Bone Marrow Aspirate Concentrate (BMAC)

Cell suspension for infusion. 50 mL of Bone Marrow Aspirate collected, and 10-15 mL BMAC injected to knee(s)

Group Type: EXPERIMENTAL

Autologous Bone Marrow Aspirate Concentrate

Intervention Type: BIOLOGICAL

Range of between 18.7 X 104 cells/mL and 21.8 X 106 cells/mL total nucleated cells (TNC)

Interventions

Autologous Bone Marrow Aspirate Concentrate

Range of between 18.7 X 104 cells/mL and 21.8 X 106 cells/mL total nucleated cells (TNC)

Intervention Type: BIOLOGICAL

Other Intervention Names

BMAC

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects ≥ 40 years old.

2. The subject must have a clinical diagnosis of osteoarthritis (OA) of one or both knees supported by radiological evidence (Kellgren Lawrence Grade II-IV) which is assessed locally (x-rays within the past 6 months of screening are acceptable).

3. Subjects whose knee pain persists for at least 12 weeks (about 3 months) prior to screening and does not improve symptoms with pain medications and non-operative treatment options.

4. Subject who has knee pain ≥ 40 mm out of 100 mm on single question VAS (Visual Analog Scale) at Screening (Visit 1) and prior to Randomization (Visit 2).

Note: Subject should meet this criterion for left and right knee separately to be eligible for bilateral study treatment.

5. The subject is willing to provide written informed consent to participate in the study after reading the informed consent form and the information provided and has had the opportunity to discuss the study with the investigator or designee.

6. The subject is able to communicate satisfactorily with the investigator and to participate in, and comply with, the requirements of the study.

7. The subject is able to understand the nature of the study and any potential hazards associated with participating in it.

8. Negative pregnancy test for female subjects of childbearing potential.

Exclusion Criteria

1. Subjects who have knee replacement surgery planned within 6 months of enrollment.

2. Subjects with a BMI ≥ 30kg/m2

3. Prior Partial Joint Replacement (PJR) or Total Joint Replacement (TJR) of one or both knees.

4. Knee surgery in the previous 6 months prior to enrollment.

5. Concomitant inflammatory disease or other condition affecting the joints (e.g., rheumatoid arthritis, septic arthritis, inflammatory joint disease, metabolic bone disease, psoriasis, gout, microcrystalline arthropathies/chondrocalcinosis, Paget's disease).

6. Congenital or acquired diseases leading to significant knee deformities that may interfere with cell application or the interpretation of results.

7. Instances of widespread pain or any pain that could interfere with the assessment of index knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee).

8. Signs of active uncontrolled infection or known history of HIV, hepatitis, or syphilis.

9. A diagnosis of any form of cancer in the previous 6 months.

10. Actively treated with oral anticoagulants or heparin therapy (treatment such as low dose Aspirin and Plavix are allowed).

11. Participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study.

12. Other conditions that may, according to medical criteria, discourage participation or impact outcome evaluation in the study.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CELL Technologies Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Riam Shamma, MD

Role: PRINCIPAL_INVESTIGATOR

CELL Technologies Inc.

Locations

Canadian Centres for Regenerative Therapy (CCRT)

Toronto, Ontario, Canada

Countries

Canada

Central Contacts

Riam Shammaa, MD

Role: CONTACT

info@celltechnologies.net

437-985-1505

Facility Contacts

Riam Shammaa

Role: primary

Other Identifiers

CLL-001

Identifier Type: -

Identifier Source: org_study_id